<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01487161</url>
  </required_header>
  <id_info>
    <org_study_id>FX006-2011-001</org_study_id>
    <nct_id>NCT01487161</nct_id>
  </id_info>
  <brief_title>Study of FX006 in Patients With Osteoarthritis of the Knee</brief_title>
  <official_title>A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Comparing FX006 to Commercially Available Triamcinolone Acetonide Injectable Suspension in Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flexion Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flexion Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the safety, efficacy and pharmacokinetics of FX006
      in patients with osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study FX006-2011-001 was a multi-center, randomized, double-blind, active comparator,
      parallel-group, single-dose study designed to assess the magnitude and duration of pain
      relief of three doses (10, 40, and 60 mg) of FX006, an extended-release formulation of TCA,
      relative to commercially-available TCA IR.

      The general tolerability of a single injection of FX006 also was assessed.

      Secondary objectives included exploration of the effect of FX006 on functional improvement,
      responder status, time to onset of pain relief, global impressions of change, and consumption
      of analgesic medications and evaluation of the PK profile of single injection of the three
      dose levels of FX006.

      The study was planned to be conducted in up to 224 male and female patients ≥40 years of age
      with OA of the knee enrolled at 22 study centers in the US, Australia, and Canada.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 8 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg</measure>
    <time_frame>8 weeks</time_frame>
    <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 10 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg</measure>
    <time_frame>10 weeks</time_frame>
    <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 12 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg</measure>
    <time_frame>12 weeks</time_frame>
    <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each of Weeks 8, 10, and 12 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 10mg and 40 mg vs TCA IR 40 mg</measure>
    <time_frame>Weeks 8, 10 and 12</time_frame>
    <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each of Weeks 1, 2, 3, 4, 5, 6, 7, 9, and 11 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score.</measure>
    <time_frame>Weeks 1-7 and Week 9 and 11</time_frame>
    <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC A (Pain Subscale) Change From Baseline at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC A1 (Pain on Walking Question) Change From Baseline at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC B (Stiffness Subscale) Change From Baseline at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC C (Function Subscale) Change From Baseline at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Responders According to OMERACT-OARSI Criteria at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Outcome Measures in Rheumatoid Arthritis Clinical Trials - Osteoarthritis Research Society International. Responders are defined as participants with high improvement in pain or function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Status as Defined by the Proportion of Patients Achieving &gt;50% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Status as Defined by the Proportion of Patients Achieving &gt;30% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Status as Defined by the Proportion of Patients Achieving &gt;20% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change Scores at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The Patient Global Impression of Change is a scale that aims to evaluate all aspects of participants' (patients') health and determining if there has been an improvement or not. The participant selects the one response from the response options that gives the most accurate description of his/her state of health (overall status). This is a 7-point scale, and scores range from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change Scores at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Clinical Global Impression of Change is a scale that the clinician uses to assess the participants' global function and determine if there has been an improvement or not. The clinician selects one response from the response options that gives the most accurate description of the participant's state of health (overall status). This is a 7-point scale, and scores range from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Weekly and Total Consumption of Rescue Medications Over 8 Weeks.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">229</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>FX006 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 3 mL intra-articular (IA) injection Extended-Release Formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FX006 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 3 mL intra-articular (IA) injection Extended-Release Formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FX006 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 3mL intra-articular (IA) injection Extended-Release Formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCA IR 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single 1 mL intra-articular (IA) injection Immediate-Release Triamcinolone Acetonide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FX006</intervention_name>
    <description>Single 3 mL intra-articular injection</description>
    <arm_group_label>FX006 10 mg</arm_group_label>
    <arm_group_label>FX006 40 mg</arm_group_label>
    <arm_group_label>FX006 60 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TCA IR</intervention_name>
    <description>Single 1 mL intra-articular injection</description>
    <arm_group_label>TCA IR 40 mg</arm_group_label>
    <other_name>Kenalog®-40 Injection</other_name>
    <other_name>Kenacort-A 40</other_name>
    <other_name>Triamcinolone Acetonide Crystalline Suspension (TAcs)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Willingness and ability to comply with the study procedures and visit schedules and
             ability to follow verbal and written instructions

          -  Male or female &gt;=40 years of age

          -  Diagnosis of unilateral or bilateral OA of the knee for at least 6 months prior to
             Screening with confirmation of OA according to American College of Rheumatology
             Criteria for Classification of Idiopathic OA of the Knee (clinical and radiological)
             based on an X-ray performed within 6 months prior to Screening or during the Screening
             period

          -  Qualifying mean score on the 24-h average pain score (0-10 numeric rating scale)

          -  Body mass index (BMI) ≤ 40 kg/m2

          -  Willingness to abstain from use of restricted medications

        Main Exclusion Criteria

          -  Ipsilateral hip OA

          -  Fibromyalgia, chronic pain syndrome or other concurrent medical or arthritic
             conditions which could interfere with the evaluation of the index knee

          -  History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing
             spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis or
             amyloidosis

          -  History of arthritides due to crystals (e.g., gout, pseudogout)

          -  History of infection in the index joint

          -  Clinical signs and symptoms of active knee infection or crystal disease of the index
             knee

          -  Presence of surgical hardware or other foreign body in the index knee

          -  Unstable joint (such as a torn anterior cruciate ligament)

          -  IA corticosteroid (investigational or marketed) in any joint within 3 months of
             Screening

          -  IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of
             Screening

          -  Oral, inhaled and intranasal corticosteroids (investigational or marketed) within 1
             month of Screening

          -  Prior arthroscopic or open surgery of the index knee within 12 months of Screening

          -  Planned/anticipated surgery of the index knee during the study period

          -  Active or history of malignancy within the last 5 years, with the exception of
             resected basal cell carcinoma, squamous cell carcinoma of the skin, or resected
             cervical atypia or carcinoma in situ

          -  Insulin-dependent diabetes

          -  Active psychiatric disorder including psychosis and major depressive disorder

          -  History of or active Cushing's syndrome

          -  Any other clinically significant acute or chronic medical conditions (e.g.,
             uncontrolled diabetes)

          -  Skin breakdown at the knee where the injection would take place

          -  Women of child-bearing potential not using effective contraception or who are pregnant
             or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Bodick, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Flexion Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Broadmeadow</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kippa-Ring</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maroochydore</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherwood</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malvern East</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Catherine's</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://journals.lww.com/jbjsjournal/Abstract/2015/06030/An_Intra_Articular,_Extended_Release_Formulation.1.aspx</url>
    <description>Journal of Bone &amp; Joint Surgery - American Volume: 3 June 2015 - Volume 97 - Issue 11 - p 877-888</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2011</study_first_submitted>
  <study_first_submitted_qc>December 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2011</study_first_posted>
  <results_first_submitted>November 2, 2017</results_first_submitted>
  <results_first_submitted_qc>December 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 12, 2018</results_first_posted>
  <disposition_first_submitted>March 16, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 16, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 3, 2015</disposition_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>knee</keyword>
  <keyword>pain</keyword>
  <keyword>corticosteroid</keyword>
  <keyword>intra-articular</keyword>
  <keyword>injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study took place at 22 centers across the United States, Canada and Australia. Enrollment took approximately 7 months.</recruitment_details>
      <pre_assignment_details>Subjects were screened within 21 days of being randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FX006 10 mg</title>
          <description>58 subjects received FX006 10 mg as a single 3 mL IA injection.</description>
        </group>
        <group group_id="P2">
          <title>FX006 40 mg</title>
          <description>59 subjects received FX006 40 mg as a single 3 mL IA injection.</description>
        </group>
        <group group_id="P3">
          <title>FX006 60 mg</title>
          <description>60 subjects received FX006 60 mg as a single 3 mL IA injection.</description>
        </group>
        <group group_id="P4">
          <title>TCA IR (40 mg)</title>
          <description>51 subjects received TCA IR 40 mg as a single 1 mL IA injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>missing data</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 229 patients were randomized to treatment in this study. 228 of 229 randomized patients received treatment and were included in the Safety Population; 1 patient randomized to the TCA IR group withdrew consent before receiving study treatment and was excluded.</population>
      <group_list>
        <group group_id="B1">
          <title>FX006 10 mg</title>
          <description>Single 3 mL IA injection</description>
        </group>
        <group group_id="B2">
          <title>FX006 40 mg</title>
          <description>Single 3 mL IA injection</description>
        </group>
        <group group_id="B3">
          <title>FX006 60 mg</title>
          <description>Single 3 mL IA injection</description>
        </group>
        <group group_id="B4">
          <title>TCA IR (40 mg)</title>
          <description>Single 1 mL IA injection</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="60"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="228"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" lower_limit="43" upper_limit="82"/>
                    <measurement group_id="B2" value="60.9" lower_limit="40" upper_limit="80"/>
                    <measurement group_id="B3" value="61.9" lower_limit="44" upper_limit="86"/>
                    <measurement group_id="B4" value="61.6" lower_limit="42" upper_limit="83"/>
                    <measurement group_id="B5" value="61.5" lower_limit="40" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 8 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg</title>
        <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
        <time_frame>8 weeks</time_frame>
        <population>All patients who receive study treatment and have baseline and at least 1 post-dose pain evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>FX006 60 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>TCA IR 40 mg</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg</title>
          <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
          <population>All patients who receive study treatment and have baseline and at least 1 post-dose pain evaluation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="0.28"/>
                    <measurement group_id="O2" value="-3.4" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1249</p_value>
            <method>Longitudinal mixed effect model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 10 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg</title>
        <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
        <time_frame>10 weeks</time_frame>
        <population>All patients who receive study treatment and have baseline and at least 1 post-dose pain evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>FX006 60 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>TCA IR 40 mg</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 10 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg</title>
          <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
          <population>All patients who receive study treatment and have baseline and at least 1 post-dose pain evaluation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="0.28"/>
                    <measurement group_id="O2" value="-3.3" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2002</p_value>
            <method>Longitudinal mixed effect model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 12 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg</title>
        <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients who receive study treatment and have baseline and at least 1 post-dose pain evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>FX006 60 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>TCA IR 40 mg</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg</title>
          <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
          <population>All patients who receive study treatment and have baseline and at least 1 post-dose pain evaluation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="0.30"/>
                    <measurement group_id="O2" value="-3.3" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5541</p_value>
            <method>Longitudinal mixed effect model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each of Weeks 8, 10, and 12 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 10mg and 40 mg vs TCA IR 40 mg</title>
        <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
        <time_frame>Weeks 8, 10 and 12</time_frame>
        <population>All patients who receive study treatment and have baseline and at least 1 post-dose pain evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>FX006 10 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>TCA IR 40 mg</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each of Weeks 8, 10, and 12 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 10mg and 40 mg vs TCA IR 40 mg</title>
          <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
          <population>All patients who receive study treatment and have baseline and at least 1 post-dose pain evaluation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="0.28"/>
                    <measurement group_id="O2" value="-4.3" spread="0.28"/>
                    <measurement group_id="O3" value="-3.4" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="0.29"/>
                    <measurement group_id="O2" value="-4.1" spread="0.29"/>
                    <measurement group_id="O3" value="-3.3" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="0.30"/>
                    <measurement group_id="O2" value="-3.7" spread="0.30"/>
                    <measurement group_id="O3" value="-3.3" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each of Weeks 1, 2, 3, 4, 5, 6, 7, 9, and 11 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score.</title>
        <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
        <time_frame>Weeks 1-7 and Week 9 and 11</time_frame>
        <population>All patients who receive study treatment and have baseline and at least 1 post-dose pain evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>FX006 10 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each of Weeks 1, 2, 3, 4, 5, 6, 7, 9, and 11 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score.</title>
          <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
          <population>All patients who receive study treatment and have baseline and at least 1 post-dose pain evaluation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="0.24"/>
                    <measurement group_id="O2" value="-3.0" spread="0.24"/>
                    <measurement group_id="O3" value="-3.0" spread="0.24"/>
                    <measurement group_id="O4" value="-3.1" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="0.27"/>
                    <measurement group_id="O2" value="-3.9" spread="0.27"/>
                    <measurement group_id="O3" value="-3.8" spread="0.27"/>
                    <measurement group_id="O4" value="-3.5" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="0.27"/>
                    <measurement group_id="O2" value="-4.1" spread="0.27"/>
                    <measurement group_id="O3" value="-4.2" spread="0.27"/>
                    <measurement group_id="O4" value="-3.5" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="0.26"/>
                    <measurement group_id="O2" value="-4.3" spread="0.26"/>
                    <measurement group_id="O3" value="-4.2" spread="0.26"/>
                    <measurement group_id="O4" value="-3.7" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="0.28"/>
                    <measurement group_id="O2" value="-4.3" spread="0.27"/>
                    <measurement group_id="O3" value="-4.2" spread="0.27"/>
                    <measurement group_id="O4" value="-3.5" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="0.28"/>
                    <measurement group_id="O2" value="-4.3" spread="0.28"/>
                    <measurement group_id="O3" value="-4.2" spread="0.28"/>
                    <measurement group_id="O4" value="-3.4" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="0.28"/>
                    <measurement group_id="O2" value="-4.4" spread="0.28"/>
                    <measurement group_id="O3" value="-3.9" spread="0.27"/>
                    <measurement group_id="O4" value="-3.3" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="0.30"/>
                    <measurement group_id="O2" value="-4.2" spread="0.30"/>
                    <measurement group_id="O3" value="-3.7" spread="0.29"/>
                    <measurement group_id="O4" value="-3.3" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="0.30"/>
                    <measurement group_id="O2" value="-3.9" spread="0.30"/>
                    <measurement group_id="O3" value="-3.2" spread="0.29"/>
                    <measurement group_id="O4" value="-3.4" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC A (Pain Subscale) Change From Baseline at Week 8</title>
        <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FX006 10 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC A (Pain Subscale) Change From Baseline at Week 8</title>
          <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="0.099"/>
                    <measurement group_id="O2" value="-1.33" spread="0.098"/>
                    <measurement group_id="O3" value="-1.16" spread="0.097"/>
                    <measurement group_id="O4" value="-0.96" spread="0.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC A1 (Pain on Walking Question) Change From Baseline at Week 8</title>
        <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FX006 10 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>FX006: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC A1 (Pain on Walking Question) Change From Baseline at Week 8</title>
          <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.12"/>
                    <measurement group_id="O2" value="-1.2" spread="0.12"/>
                    <measurement group_id="O3" value="-1.1" spread="0.11"/>
                    <measurement group_id="O4" value="-0.8" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC B (Stiffness Subscale) Change From Baseline at Week 8</title>
        <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FX006 10 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR (40 mg)</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC B (Stiffness Subscale) Change From Baseline at Week 8</title>
          <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="0.113"/>
                    <measurement group_id="O2" value="-1.49" spread="0.112"/>
                    <measurement group_id="O3" value="-1.24" spread="0.111"/>
                    <measurement group_id="O4" value="-0.99" spread="0.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC C (Function Subscale) Change From Baseline at Week 8</title>
        <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FX006 10 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC C (Function Subscale) Change From Baseline at Week 8</title>
          <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="0.096"/>
                    <measurement group_id="O2" value="-1.31" spread="0.096"/>
                    <measurement group_id="O3" value="-1.13" spread="0.095"/>
                    <measurement group_id="O4" value="-0.94" spread="0.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Responders According to OMERACT-OARSI Criteria at Week 8</title>
        <description>Outcome Measures in Rheumatoid Arthritis Clinical Trials - Osteoarthritis Research Society International. Responders are defined as participants with high improvement in pain or function.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FX006 10 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Responders According to OMERACT-OARSI Criteria at Week 8</title>
          <description>Outcome Measures in Rheumatoid Arthritis Clinical Trials - Osteoarthritis Research Society International. Responders are defined as participants with high improvement in pain or function.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Status as Defined by the Proportion of Patients Achieving &gt;50% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8</title>
        <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FX006 10 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Status as Defined by the Proportion of Patients Achieving &gt;50% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8</title>
          <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Status as Defined by the Proportion of Patients Achieving &gt;30% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8</title>
        <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FX006 10 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Status as Defined by the Proportion of Patients Achieving &gt;30% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8</title>
          <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Status as Defined by the Proportion of Patients Achieving &gt;20% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8</title>
        <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FX006 10 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Status as Defined by the Proportion of Patients Achieving &gt;20% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8</title>
          <description>The pain intensity score is measured using an 11-point numeric rating scale (NRS), where 0 indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine.&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Change Scores at Week 8</title>
        <description>The Patient Global Impression of Change is a scale that aims to evaluate all aspects of participants' (patients') health and determining if there has been an improvement or not. The participant selects the one response from the response options that gives the most accurate description of his/her state of health (overall status). This is a 7-point scale, and scores range from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FX006 10 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Change Scores at Week 8</title>
          <description>The Patient Global Impression of Change is a scale that aims to evaluate all aspects of participants' (patients') health and determining if there has been an improvement or not. The participant selects the one response from the response options that gives the most accurate description of his/her state of health (overall status). This is a 7-point scale, and scores range from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.16"/>
                    <measurement group_id="O2" value="1.8" spread="0.16"/>
                    <measurement group_id="O3" value="2.4" spread="0.16"/>
                    <measurement group_id="O4" value="2.5" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Change Scores at Week 8</title>
        <description>The Clinical Global Impression of Change is a scale that the clinician uses to assess the participants' global function and determine if there has been an improvement or not. The clinician selects one response from the response options that gives the most accurate description of the participant's state of health (overall status). This is a 7-point scale, and scores range from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FX006 10 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Change Scores at Week 8</title>
          <description>The Clinical Global Impression of Change is a scale that the clinician uses to assess the participants' global function and determine if there has been an improvement or not. The clinician selects one response from the response options that gives the most accurate description of the participant's state of health (overall status). This is a 7-point scale, and scores range from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.16"/>
                    <measurement group_id="O2" value="1.8" spread="0.16"/>
                    <measurement group_id="O3" value="2.5" spread="0.16"/>
                    <measurement group_id="O4" value="2.6" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Weekly and Total Consumption of Rescue Medications Over 8 Weeks.</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FX006 10 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O2">
            <title>FX006 40 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O3">
            <title>FX006 60 mg</title>
            <description>FX006: Single 3 mL IA injection</description>
          </group>
          <group group_id="O4">
            <title>TCA IR 40 mg</title>
            <description>TCA IR: Single 1 mL IA injection</description>
          </group>
        </group_list>
        <measure>
          <title>Average Weekly and Total Consumption of Rescue Medications Over 8 Weeks.</title>
          <units>tablets (1tablet= 500 mg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.22"/>
                    <measurement group_id="O2" value="1.0" spread="0.22"/>
                    <measurement group_id="O3" value="1.1" spread="0.22"/>
                    <measurement group_id="O4" value="1.2" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from post injection on Day 1 through Day 85</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FX006 10 mg</title>
          <description>FX006: Single 3 mL IA injection</description>
        </group>
        <group group_id="E2">
          <title>FX006 40 mg</title>
          <description>FX006: Single 3 mL IA injection</description>
        </group>
        <group group_id="E3">
          <title>FX006 60 mg</title>
          <description>FX006: Single 3 mL IA injection</description>
        </group>
        <group group_id="E4">
          <title>TCA IR (40 mg)</title>
          <description>TCA IR: Single 1 mL IA injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngits</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Inreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthalgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Joint Stiffness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott Kelley, VP of Medical Affairs</name_or_title>
      <organization>Flexion Therapeutics</organization>
      <phone>781-305-7142</phone>
      <email>skelley@flexiontherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

